论文部分内容阅读
应用ＬＳＡＢ免疫组织化学法，研究转移抑制基因ｎｍ２３－Ｈ１蛋白在乳腺浸润性癌（ＩＢＣ）中的表达与转移及预后的关系。结果：１．ｎｍ２３－Ｈ１蛋白在ＩＢＣ中阳性率为６９．７６％（６０／８６）。２．发生骨、肺、肝、脑等远处转移者原发灶ｎｍ２３－Ｈ１蛋白表达率５５．８８％（１９／３４）低于随访五年以上未发现转移者的表达率８７．５％（２１／２４），两者差异有显著意义（Ｐ＜０．０１）。３．ｎｍ２３－Ｈ１蛋白表达与临床分期显著相关（Ｐ＜０．０１）。４．ｎｍ２３－Ｈ１蛋白在原发灶的表达越高患者生存期越长，生存５年以上者表达率为９１．６６％（３３／３６），生存不足五年者表达率为５６％（２８／５６），两者差异有非常显著意义（Ｐ＜０．００１）。５．ｎｍ２３－Ｈ１蛋白表达与腋窝淋巴结转移无显著相关性（Ｐ＞０．０５）。而腋窝淋巴结无转移的２５例，ＩＢＣ原发灶ｎｍ２３－Ｈ１蛋白表达仍与生存期相关。本研究结果表明：ｎｍ２３－Ｈ１蛋白表达与远处转移及ＴＭＮ分期呈负相关，与生存期呈正相关。因此ｎｍ２３－Ｈ１蛋白表达可以作为ＩＢＣ转移和预后的有益指标。
The expression of metastasis suppressor gene nm23-H1 in breast invasive carcinoma (IBC) was studied by LSAB immunohistochemical method. Results: 1. The positive rate of nm23-H1 protein in IBC was 69.76% (60/86). 2. The expression rate of nm23-H1 protein in the primary tumors of patients with distant metastases such as bone, lung, liver, and brain was 55.88% (19/34), which was lower than the expression rate of 87.5% of those who did not find metastasis more than five years after follow-up (21 /24), there was a significant difference between the two (P<0.01). 3. The expression of nm23-H1 protein was significantly associated with clinical stage (P<0.01). 4. The higher the expression of nm23-H1 protein in the primary tumor was, the longer the survival time was, the survival rate was 91.66% (33/36) in those who survived more than 5 years, and the expression rate was 56% in those who survived less than 5 years (28/56). ), the difference between the two is very significant (P <0.001). 5. There was no significant correlation between nm23-H1 protein expression and axillary lymph node metastasis (P>0.05). In 25 cases with no metastasis of axillary lymph nodes, the expression of nm23-H1 protein in IBC primary lesions was still associated with survival. The results of this study indicate that the expression of nm23-H1 protein is negatively correlated with distant metastasis and TMN stage and positively correlated with survival time. Therefore, nm23-H1 protein expression may serve as a useful indicator of metastasis and prognosis of IBC.